Jansitin Duo (Metformin Hydrochloride, Sitagliptin)

Metformin decreases hepatic glucose output and increases peripheral insulin sensitivity, while sitagliptin blocks the DPP‑4 enzyme, raising endogenous incretin levels. This dual action reduces blood glucose by both limiting production and enhancing insulin‑mediated uptake, providing complementary mechanisms for better glucose regulation.

The specific dose of Jansitin Duo is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and concomitant therapies. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose without medical guidance.

Safety of Jansitin Duo in pregnancy or lactation has not been fully established. The prescriber must weigh potential benefits against possible risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To request Jansitin Duo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Compared with monotherapy options, Jansitin Duo offers a fixed‑dose combination that simplifies dosing and may improve adherence. It provides the glucose‑lowering benefits of metformin plus the incretin‑based effect of sitagliptin, which can be more effective than either agent alone and avoids the need for separate tablets.

Jansitin Duo should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Jansitin Duo is taken orally, usually once daily with a meal to reduce gastrointestinal discomfort. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal metabolic complication linked to metformin, and pancreatitis, an inflammation of the pancreas associated with sitagliptin. Patients should seek immediate medical attention if they experience severe abdominal pain, unexplained weakness, or rapid breathing.

Jansitin Duo is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, acute or chronic metabolic acidosis, and those with a history of lactic acidosis. It should also be used with caution in individuals with significant liver disease.